A tweaked LNP formula cut liver accumulation while keeping local delivery intact

Key Findings

🔁 Swapping PEG Chemistry Won't Fix Your Repeat-Dose Problem

• After a first LNP dose triggers antibodies against PEG — the stabilizing polymer coating most nanoparticles — changing the PEG type, concentration, mRNA cargo, or injection route on the second dose made no difference: efficacy still collapsed.
• The culprit appears to be the ionizable lipid itself. Lipids that engage certain innate immune receptors seem to prevent the anti-PEG response from forming in the first place; those that don't leave the door open for antibody-driven neutralization of every subsequent dose, including FDA-approved formulations.

❄️ Trehalose Outperforms Sucrose When the Freezer Is Gone

• Freeze-dried mRNA-LNPs stored at 40°C — think tropical warehouse, not lab fridge — held up significantly better when trehalose was used as the stabilizing sugar instead of the industry-standard sucrose, owing to trehalose's higher glass transition temperature in its amorphous form.
• Mannitol, a common pharmaceutical excipient, was a clear loser: it crystallized during freeze-drying and damaged nanoparticle structure, tanking encapsulation efficiency.

🦠 mRNA-Encoded Antibody Combo Blocks COVID Escape in Mice

• Scientists engineered mRNA that, once injected in LNPs, instructs the body to produce a trio of bispecific antibodies — each designed to grip two different viral targets simultaneously — achieving serum neutralizing titers above 1:10,000 in mice and broad coverage of variants including the heavily mutated BA.3.2.2 lineage.
• Mice given the combination before exposure to XBB.1.5 lost less weight and carried lower lung viral loads than controls, suggesting the approach can act as a pre-exposure shield against rapidly mutating pathogens.

🦷 Bone-Anchored LNPs Deliver RNA Without Washing Away

• A new platform called MiTEX uses bisphosphonate-modified lipid nanoparticles that chemically grip hydroxyapatite — the mineral in bone and teeth — resisting fluid clearance and providing sustained RNA delivery to nearby cells.
• In two proof-of-concept tests, the system labeled new bone formation in live mice using Cre mRNA and reduced inflammation markers in human gum tissue using gene-silencing RNA, suggesting versatility across regenerative and immune applications.

👂 LNP Delivery Route Determines Which Ear Cells Get the Message

• Mapping mRNA-LNP distribution in newborn mouse cochleae revealed a stark split: injection through the round window membrane reached the spiral ligament, stria vascularis, and auditory nerve region but missed hair cells entirely, while injection into the fluid-filled scala media reached hair cells but stayed confined to that compartment.
• Neither route achieved whole-cochlea coverage, meaning hearing gene therapy will likely require route combinations or new formulations tailored to specific cell targets.

💉 Optimized Epitope Flanking Sequences Boosted Tumor Vaccine Responses in Mice

• In a mouse tumor model, an mRNA cancer vaccine encoding tumor antigens surrounded by computationally optimized flanking amino acids cleared established tumors and generated robust, diverse CD8+ T cell responses, while the same antigens with natural flanking sequences produced weaker immunity and incomplete protection.
• Immunopeptidomics confirmed the optimized version increased how densely tumor-derived peptides were displayed on cell surfaces — more display translated directly into stronger and more durable immune memory.